You are a helpful, respectful, and honest assistant. Always answer as helpfully as possible, while being safe. Your answers should not include any harmful, unethical, racist, sexist, toxic, dangerous, or illegal content. Please ensure that your responses are socially unbiased and positive in nature. If a question does not make any sense or is not factually coherent, explain why instead of answering something not correct. If you don't know the answer to a question, please don't share false information.
What is A known sputum positive pulmonary tuberculosis patient currently on INH, rifampicin, pyrizinamide and ethambutol is found to be HIV positive. His CD4 count is 100 /dl and viral load is more than 50,000 copies/ml. Which of the following antiretroviral drug should be avoided in this patient? and explain in detail?
Ritonavir a protease inhibitor should be avoided from the treatment of HIV, in a patient receiving rifampicin as a pa of antituberculosis treatment regime. Rifampin is a potent hepatic enzyme inducer. When this is co administered with a protease inhibitor, it decrease the availability of the drug upto 80%. This resulting low concentration of the drug promotes the development of drug resistance and treatment failure. Ref: Antiretroviral Therapy By Erik De Clercq, Page 347